|
Medical Device Boasts Encouraging Data for Hepatitis C Treatment
A medical device designed to clear viruses and immunosuppressive proteins from the blood reduced Hepatitis C viral load for several people on dialysis. Further case studies will determine if the Aethlon Hemopurifier® can induce a rapid virological response against Hepatitis...
Hepatitis C Study Increases Interest in SCV-07
Trial results show SciClone's SCV-07 effectively reduces Hepatitis C viral load in previous non-responders with genotype 1. Based on these encouraging results, a follow-up study to evaluate SCV-07's potential to replace or improve the current Hepatitis C standard treatment will...
New Hope for HCV
Funded by Pfizer, Tacere's licensed RNAi technology could change the way Hepatitis C is treated. A mechanism that inhibits genes from transferring information and creating new genetic material, RNAi-based drugs may be able to silence the genes that cause disease....
|
|
|
|
Hepatitis A General Clinical Tests
|
Test Name
Method |
Hepatitis A Antibody (Anti-HA, Anti-HAV, Total Anti-HA, IgG-anti-HA,
IgM-anti-HA. Total (IgG + IgM) Anti-HA IRMA, IEMA
IgM-anti-HA Anti-µ capture |
Specimen
Requirements |
Serum
Stable for 7 d at RT and indefinitely at 4°C or -20° |
Ref. Range
Conventional
International Recommended Units |
Negative
|
Chemical Interfaces
In Vivo Effects |
None Found
|
| Diagnostic Information |
Hepatitis A, formerly called infectious hepatitis, is a picornavirus
transmitted through either oral or fecal contact that can cause either
asymptomatic infection or symptomatic clinical hepatitis. Both IgG
and IgM antibodies occur early in the acute infection with IgG persisting
for years. Diagnosis of acute HAV infection requires positivity dor
IgM-anti-HA. Afteran acute infection, IgM-anti-HA usually disappears
in 3-4 mo but may persist up to 10 mo. Patients with IgG-anti-HA are
protected from the virus. Hepatitis A never causes chronic infection,
and acute relapses occasionally occur. When Hepatitis A vaccine becomes
available and is widely used, the existing assays may not be sensitive
enough to detect post-vaccination autoantibodies which appear at relatively
low titers. |
| Remarks |
A high percentage of the population has protective antibody to the
Hepatitis A virus (total anti-HA) acquired from clinically unapparent
infections. This is why standard immune globulin has been effective
as prophylaxis for Hepatitis A exposures. |
References:
Clinical Guide to Laboratory Tests, third edition.
|
|
|
|
